DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Update

DBV Technologies S.A. (NASDAQ:DBVT) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 298,500 shares, a growth of 7.1% from the August 31st total of 278,800 shares. Based on an average daily volume of 48,300 shares, the days-to-cover ratio is presently 6.2 days. Approximately 0.3% of the shares of the stock are sold short.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $0.72 on Wednesday. The firm has a market capitalization of $69.43 million, a price-to-earnings ratio of -0.86 and a beta of 0.68. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $2.74. The stock has a 50 day moving average of $0.85 and a 200 day moving average of $1.05.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same quarter in the previous year, the company posted ($0.26) earnings per share. Analysts forecast that DBV Technologies will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. StockNews.com started coverage on DBV Technologies in a report on Friday, September 27th. They issued a “hold” rating for the company. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.